Counter-Strike: Nice Try vs GenOne (BO3) - NODWIN Clutch Series Group Stage

Según los datos más recientes del mercado de predicción para la consulta “Counter-Strike: Nice Try vs GenOne (BO3) - NODWIN Clutch Series Group Stage”, los operadores han formado un fuerte consenso.

Actualmente, Match Winner domina el mercado con una abrumadora probabilidad de victoria del 9995%. O/U 2.5 Games le sigue en segundo lugar con 9995%, mientras que Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5) se sitúa tercero con 6250%. El volumen de apuestas de este mercado ya alcanza $90,3K, lo que refleja un enorme interés.

Para evaluar mejor la posición de cada resultado posible, el mercado puede segmentarse en tres niveles de negociación según la probabilidad implícita y el precio de los contratos:

🥇 Nivel 1: El líder dominante

• Match Winner (9995%): Con la probabilidad más alta, Match Winner cuenta con un fuerte respaldo del libro de órdenes. Quienes quieran apostar por este resultado se enfrentan a un precio de contrato “Buy Yes” de 9995¢, señal de una gran convicción del mercado. Solo este contrato ha generado $48.0K de volumen.

🥈 Nivel 2: Los principales aspirantes

• O/U 2.5 Games (9995%): Como la alternativa más viable, O/U 2.5 Games mantiene una probabilidad del 9995% de resolverse a favor. Sus acciones “Buy Yes” cotizan actualmente a 9995¢.
• Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5) (6250%): En tercer lugar con una probabilidad del 6250%, el mercado muestra un escepticismo prudente hacia Map 3 Rounds Handicap: Nice Try (-3.5) vs GenOne (+3.5), tratándolo como un comodín externo salvo que cambie el impulso.

🥉 Nivel 3: Las opciones de cola larga (suman ~0%)

Más allá de las tres primeras opciones, se sigue un amplio campo de variables macro y resultados poco probables. Aunque sus probabilidades individuales son bajas, son coberturas clave para los operadores especulativos:

• Opciones alternativas: Esto incluye Map 3 Rounds Handicap: Nice Try (-6.5) vs GenOne (+6.5) (5650%), Map 3 Rounds Handicap: GenOne (-3.5) vs Nice Try (+3.5) (4350%) y Map 3 Rounds Handicap: Nice Try (-12.5) vs GenOne (+12.5) (4350%).
• Volumen especulativo: A pesar de su baja probabilidad estadística, ciertos contratos de cola larga como Map 3 Total Rounds: Over/Under 21.5 siguen atrayendo un interés notable.

This market refers to the Counter-Strike Round 1 match between Nice Try and GenOne in the NODWIN Clutch Series Group Stage, initially scheduled for November 10, 2026 at 1:00 PM ET.

This market will resolve to "Nice Try" if Nice Try win the match against GenOne.

This market will resolve to "GenOne" if GenOne win the match against Nice Try.

If the match is canceled (not played at all) or ends in a tie, this market will resolve to 50-50.

If the match is postponed, it must be rescheduled to a start time on or before November 24, 2026 at 11:59 PM ET (14 calendar days after the originally scheduled start of November 10, 2026 at 1:00 PM ET). If, by that deadline, the most recently announced rescheduled start time is on or before the deadline, this market resolves based on the result of the match as played. Otherwise, this market resolves 50-50, regardless of whether the match is subsequently played.

If the match begins but is not completed, and one team wins due to the opponent's forfeiture, disqualification, or walkover, this market will resolve to the team who wins.

If the match ends in a forfeit, disqualification, or walkover (team withdraws before the start and the other wins automatically), this market will resolve to 50-50.

The resolution source for this market will be official information from https://hltv.org. However, if https://hltv.org has not published final results within 2 hours after the event’s conclusion, a consensus of credible reporting may be used instead including video evidence.

In cases where a team’s listed name includes minor discrepancies from the resolution source, this market will resolve based on the underlying real-world match rather than exact name matching. Recognizable abbreviations, alternate or erroneous spellings, sponsor tags, affiliate or academy designations, regional identifiers, and minor formatting differences will be treated as referring to the same team, provided the intended team can be clearly and uniquely identified within the relevant competition. If a listed team name has no reasonable connection to any participating team, or if it matches or could reasonably refer to another team in the same competition such that the intended team cannot be unambiguously determined, this market will resolve 50-50.